Skip to main content
Top
Published in: Diabetologia 9/2021

01-09-2021 | Pancreas Transplantation | Letter

Donor insulin use during stay in the intensive care unit should not preclude pancreas transplantation

Authors: Pedro Ventura-Aguiar, Enrique Montagud-Marrahi, Antonio J. Amor, Fritz Diekmann

Published in: Diabetologia | Issue 9/2021

Login to get access

Excerpt

To the Editor: In a recent issue of Diabetologia, Shapey et al reported the short-term outcomes of pancreas transplantation with organs from donors who required insulin use during their period of stay on the intensive care unit (ICU) prior to pancreas donation [1]. The major finding of this retrospective registry analysis was a direct relationship between donor insulin use (DIU) and an increased risk for early graft failure due to isolated islet failure (OR 1.79 [95% CI 1.05, 3.07]). This is a major topic in the pancreas transplant community since islet cell damage induced by brain-death or pre-procurement therapies may present an add-on risk for graft failure to that associated with ischaemia-reperfusion-induced injury and post-transplant steroid and immunosuppression treatment. Nonetheless, the conclusions should be read with caution due to some methodological biases, and the extrapolation of the results towards decision taking (e.g., by transplant teams when deciding whether to accept or discard a pancreas for transplantation) should be done with care due to the concerns outlined below. …
Literature
Metadata
Title
Donor insulin use during stay in the intensive care unit should not preclude pancreas transplantation
Authors
Pedro Ventura-Aguiar
Enrique Montagud-Marrahi
Antonio J. Amor
Fritz Diekmann
Publication date
01-09-2021
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05479-3

Other articles of this Issue 9/2021

Diabetologia 9/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.